PCN57 PATIENT REPORTED OUTCOMES IN LABELING FOR ONCOLOGY PRODUCTS: REVIEW OF FDA AND EMEA LABELS  by Caron, M et al.
A141Abstracts
emotion (p = 0.048, p = 0.015). CONCLUSION: As expected,
the patients had lower HRQL and increased emotional morbid-
ity when neutropenic. Parental reports provide evidence that the
Turkish translation is acceptable, understandable and has con-
struct validity for assessing health-status in childhood cancer
patients.
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OBJECTIVES: The functional status of individuals and their self-
rated quality of life has been shown to be an important predic-
tor of general quality of life, mortality, and utilization of health
services. We investigated the factors associated with physical
function (PF) and general health (GH) at baseline in patients with
prostate cancer as well as factors associated with changes over
the course of disease. METHODS: Data from CaPSURE, a lon-
gitudinal disease registry of men with prostate cancer, was used
to identify a group of men who were newly diagnosed with
prostate cancer, have deﬁned initial treatment, and had one pre-
treatment and at least two years of post-treatment HRQOL
assessments. HRQOL were measured by SF-36 and were
assessed bi-annually. Changes in PF and GH scores over time
were evaluated by mixed model analysis, accounting for type of
treatment received, time of HRQOL assessment, age at diagno-
sis, level of function at baseline, and education level. RESULTS:
3625 patients met the study criteria. At baseline high level of
physical functioning and general health (median 95 and 75
respectively) were demonstrated. In multivariate mixed model
analysis type of treatment, baseline level of physical function,
time of HRQOL assessment, age, education level, and interac-
tion term between time and type of treatment were signiﬁcantly
associated with changes in PF and GH over time. Differences in
PF and GH persisted through the period of study and varied
greatly depending on level of function at baseline (adjusted
means 62.7 vs. 95.2 for PF and 62.1 vs. 78.0 for GH at ﬁrst year
after treatment). CONCLUSION: Further evaluation of the rela-
tionship between GH and PF can provide us with important
information to identify critical elements of HRQOL. Identiﬁca-
tion of the speciﬁc determinants of perceived and objective
measure could provide us with tools for improving overall
quality of life in patients with prostate cancer.
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OBJECTIVES: To review the oncology products approved in the
United States and in Europe with a particular focus on the
Patient-Reported Outcome (PRO) end-points appearing in the
products’ labels. METHODS: Oncology products approved in
Europe since 1995 through the centralized procedure and in the
United States since 1998 (new molecular entities) were identiﬁed
directly from our internal resources resulting from a review of
the EMEA and FDA websites. Using the PROLabels database,
we identiﬁed the products indicated for cancer treatment and
showing evidence of PRO in labeling. PRO Labels is a unique
on-line tool which provides information on the drug products
for which the FDA and/or the EMEA have granted a PRO label-
ing claim RESULTS: Overall, 36 different products indicated for
the treatment of cancer were identiﬁed in this review, 12 of which
were approved both in Europe and in the U.S. Of these 36
approved drugs, 7 contained descriptions of Patient-Reported
Outcomes in the labeling. Two drugs were approved in the US
with PRO data used to assess health-related quality of life
(HRQL), treatment satisfaction and subjective assessment of
lesions. In Europe, 5 products used PRO data to capture HRQL,
pain, and symptoms. These products were different from the US
ones. Regarding the methods to measure PRO, 5 products used
a deﬁned instrument, one used a single item and another used a
questionnaire which was not speciﬁed. CONCLUSION: Overall,
PRO data in labeling for oncology products is not frequent
(between 8 and 20% of approved products), and is comparable
with the average rate over all therapeutic areas (source PROLa-
bels). The location of PRO endpoints was mainly in the clinical
studies section. An interesting ﬁnding is the lack of overlap
between the American and the European PRO claims.
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OBJECTIVES: The objective of this study was to compare
ciproﬂoxacin 0.3%/dexamethasone 0.1% (CD) otic suspension
to polymyxin B/neomycin/hydrocortisone (PNH) otic suspension
for the treatment of acute otitis externa (AOE). METHODS:
Data from two randomized AOE clinical trials were pooled
together for this analysis. AOE patients randomly received either
CD, 3–4 drops twice a day for seven days, or PNH, 3–4 drops
three times a day for seven days. Clinical assessment of ear
inﬂammation, ear tenderness, ear edema and ear discharge were
performed on days 3, 8 and 18 of the study. Inﬂammation and
edema were evaluated using the following four point scale: none
= 0, mild = 1, moderate = 2, severe = 3. Ear tenderness and otic
discharge were rated on a scale where absent = 0 and present =
1. A composite clinical score with a range of 0 to 8 was used as
the ﬁnal outcomes measure. Clinical cure was deﬁned as com-
posite clinical score of zero. A Kaplan-Meier survival analysis
with a log-rank test was used to compare the cure rates between
treatment groups. RESULTS: A total of 1072 patients (1242
ears) were included in the analysis (537 CD patients and 535
PNH patients). Both treatment groups were similar with respect
to baseline AOE severity and demographic parameters. The log-
rank test revealed a signiﬁcant (p = 0.0380) difference in AOE
cure rates between the CD and PNH groups. The Kaplan-Meier
analysis indicated that CD patients were cured 0.6 days sooner
than PNH patients (9.7 versus 10.3 days, respectively) and the
time needed to cure 75% of the CD group was 8 days compared
to 18 days for the PNH group. CONCLUSION: CD appears to
be superior to PNH for the treatment of AOE due to its faster
cure rate.
